Blar i NTNU Open på forfatter "Hjorth-Hansen, Henrik"
-
CD36 Defines Primitive Chronic Myeloid Leukemia Cells Less Responsive To Imatinib But Vulnerable To Antibody-Based Therapeutic Targeting
Landberg, Niklas; von Palffy, Sophia; Askmyr, Maria K.; Lilljebjörn, Henrik; Sanden, Carl; Rissler, Marianne; Mustjoki, Satu; Hjorth-Hansen, Henrik; Richter, Johan; Ågerstam, Helena; Järås, Marcus; Fioretos, Thoas (Journal article; Peer reviewed, 2018)Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are their low efficacy in eradicating the ... -
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Berentsen, Sigbjørn; Barcellini, Wilma; D'Sa, Shirley; Randen, Ulla; Tvedt, Tor Henrik Anderson; Fattizzo, Bruno; Haukås, Einar; Kell, Megan; Brudevold, Robert; Dahm, Anders Erik Astrup; Dalgaard, Jakob; Frøen, Hege; Hallstensen, Randi; Jæger, Pernille Horgmo; Hjorth-Hansen, Henrik; Malecka, Agnieszka Maria; Oksman, Markku; Rolke, Jürgen; Sekhar, Mallika; Sørbø, Jon Hjalmar; Tjønnfjord, Eirik; Tsykunova, Galina; Tjønnfjord, Geir Erland (Peer reviewed; Journal article, 2020)We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we ... -
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
Rio-Machin, Ana; Villiamy, Tom; Hug, Nele; Walne, Amanda; Tawana, Kiran; Cardoso, Shirleny; Ellison, Alicia; Pontikos, Nikolas; Wang, Jun; Tummala, Hemanth; Al Seraihi, Ahad Fahad H.; Alnajar, Jenna; Bewicke-Copley, Findlay; Barnett, Michael; Armes, Hannah; Bloor, Adrian; Bödör, Csabo; Bowen, David; Fenaux, Pierre; Green, Andrew; Hallahan, Andrew; Hjorth-Hansen, Henrik; Hossein, Upal; Killick, Sally; Lawson, Sarah; Layton, Mark; Male, Alison M.; Marsh, Judith; Mehta, Priyanka; Mous, Rogier; Nomdedéu, Josep F.; Owen, Carolyn; Pavlu, Jiri; Payne, Elspeth; Protheroe, Rachel E.; Preudhomme, Claude; Pujol-Moix, Nuria; Renneville, Aline; Russell, Nigel; Saggar, Anand; Sciuccati, Gabriela; Taussig, David; Toze, Cynthia; Uyttebroeck, Anne; Vandenberghe, Peter; Schlegelberger, Brigitte; Ripperger, Tim; Steinemann, Doris; Wu, John; Mason, Joanne; Page, Paula; Akiki, Susanna; Reay, Kim; Cavenagh, Jamie D.; Plagnol, Vincent; Caceres, Javier F.; Fitzgibbon, Jude; Dokal, Inderjeet (Peer reviewed; Journal article, 2020)The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we ... -
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)
Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Mohammed Waleed; Markevärn, Berit; Ohm, Lotta; Olsson-Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Bengt; Porkka, Kimmo; Mustjoki, Satu; Richter, Johan (Journal article, 2015)We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. ... -
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
Pietarinen, Paavo O; Eide, Christopher A; Ayuda-Duran, Maria del Pilar; Potdar, Swapnil; Kuusanmäki, Heikki; Andersson, Emma I; Mpindi, John P; Pemovska, Tea; Kontro, Mika; Heckman, Caroline A.; Kallioniemi, Olli; Wennerberg, Krister; Hjorth-Hansen, Henrik; Druker, Brian J; Enserink, Jorrit; Tyner, Jeffrey W.; Mustjoki, Satu; Porkka, Kimmo (Peer reviewed; Journal article, 2017)Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there is limited ... -
Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia
El Missiry, Mohamed; Hjorth-Hansen, Henrik; Richter, Johan; Olson-Strömberg, Ulla; Stenke, Leif; Porkka, Kimmo; Kreutzman, Anna; Mustjoki, Satu (Journal article; Peer reviewed, 2017)n chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of ... -
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, Andreas; Baccarani, Michele; Silver, Richard T.; Schiffer, Charles A.; Apperley, Jane F.; Cervantes, Francisco; Clark, Richard E.; Cortes, Jorge Eduardo; Deininger, Michael Werner Nikolaus; Guilhot, François; Hjorth-Hansen, Henrik; Hughes, Timothy Peter; Janssen, Jeroen J.W.M.; Kantarjian, Hagop M.; Kim, Dong-Wook; Larson, Richard A.; Lipton, Jeffrey Howard; Mahon, François-Xavier; Mayer, Jiří; Nicolini, Franck Emmanuel; Niederwieser, Dietger Walter; Pane, Fabrizio; Radich, Jerald P.; Réa, Delphine; Richter, Johan; Rosti, Gianantonio; Rousselot, Philippe; Saglio, Giuseppe; Saußele, Susanne; Soverini, Simona; Steegmann, Juan Luis; Turkina, Anna; Zaritskey, Andrey Yu.; Hehlmann, Rüediger (Peer reviewed; Journal article, 2020)The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep ... -
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M.J.; Lähteenmäki, Hanna; Kasanen, Tiina; Klievink, Jay; Olsson-Strömberg, Ulla; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Söderlund, Stina; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Tobias; Gjertsen, Bjørn Tore; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Dimitrijevic, Andreja; Udby, Lene; Bjerrum, Ole Weis; Hjorth-Hansen, Henrik; Mustjoki, Satu (Peer reviewed; Journal article, 2022)In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising ... -
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Kreutzman, Anna; Yadav, Bhagwan; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Lee, Moon Hee; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lofti, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, Henrik; Mustjoki, Satu (Peer reviewed; Journal article, 2019)Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and ... -
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh; Markevärn, Berit; Själander, Anders; Stenke, Leif; Deneberg, Stefan; Ahlstrand, Erik; Myhr-Eriksson, Kristina; Panayiotidis, Panayiotis; Gedde-Dahl, Tobias; Žáčková, Daniela; Mayer, Jiří; Olsson-Strömberg, Ulla; Mahon, Francois-Xavier; Saussele, Susanne; Hjorth-Hansen, Henrik; Koskenvesa, Perttu (Peer reviewed; Journal article, 2021) -
Novel cytokines in growth control and bone disease of multiple myeloma
Hjorth-Hansen, Henrik (Dissertations at the Faculty of Medicine, 0805-7680; 182, Doctoral thesis, 2001)Myelomatose (benmargskreft) er en blodsyk dom som rammer ca 200 nordmenn årlig. Sykdommen kan ikke kureres og karakteriseres av symptomer som benmargssvikt og infeksjonstendenns, men kanskje først og fremst av sykelig ... -
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore (Journal article; Peer reviewed, 2017)Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis, but has so far not been tested in a clinical trial of targeted ...